(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Schweizer described a single-center phase II trial testing olaparib in combination with Bipolar Androgen Therapy (BAT) for men with metastatic castration-resistant prostate cancer (mCRPC). BAT leads to a rapid fluctuation in testosterone (T) between near-castrate and supraphysiologic levels and has shown promise in mCRPC. Additionally, it’s postulated that BAT effects may be mediated through induction of DNA damage. Thus, preclinical studies suggest synergy in combination with the PARP inhibitor olaparib.